Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor. Durvalumab blocks the interactions of PD-L1 with programmed cell death protein 1 (PD-1) and CD80, with IC₅₀ values of 0.1 and 0.04 nM, respectively. Durvalumab can be used in research on various types of cancer, including non-small cell lung cancer (NSCLC) and advanced hepatocellular carcinoma.

PD-1/PD-L1:0.1 nM, PD-L1/CD80:0.04 nM

Method: Cancer cell lines (MDA-MB-231 triple-negative breast cancer cell line and AsPC-1 pancreatic cancer cell line) were incubated with Durvalumab at concentration of 10μg/mL at 4°C overnight. PD-L1 expression was verified in the MDA-MB-231 and AsPC-1 cell lines by flow cytometry.
Result: Durvalumab shows specificity for PD-L1.^[2]

Method: NOD/SCID mice bearing HPAC tumors co-implanted with primary human T cells received intraperitoneal injections of durvalumab at doses of 5, 1, 0.1, or 0.01 mg/kg twice weekly for 3 weeks. NOD/SCID mice bearing A375 tumors co-implanted with primary human T cells received intraperitoneal injections of durvalumab at doses of 5, 1, or 0.1 mg/kg twice weekly for 3 weeks.
Result: Durvalumab significantly inhibited tumor growth in both HPAC and A375 xenograft models compared with an isotype-matched control antibody. ^[1]
Method: 5×10^6 MDA-MB-231 cells and 4×10^6 AsPC-1 cells were implanted subcutaneously on the right shoulder of each mouse.Tumor xenograft mice (n = 3/group) were injected with 3.7-7.4 MBq (0.10-0.20 mCi) of 64^Cu-NOTA_x0002_Durvalumab/NOTA-IgG via the lateral tail vein. PET/CT scans were acquired at 4, 24, and 48 h post-injection (p.i.).
Result: 64^Cu-NOTA_x0002_Durva showed longer blood retention in the non-targeting group.^[2]

CHO

Human

Immobilized Human PD-L1 Protein (His) (TMPY-04343) at 1 μg/mL (100 μL/well) can bind Durvalumab. The EC50 is 1.210 ng/mL.

Monoclonal

Unconjugated